According to an Associated Press report based on a study published in the New England Journal of Medicine today, the widely used chemotherapy drug Taxol does not work for the most common form of breast cancer and helps far fewer patients than has been believed.
If further study bears this out, more than 20,000 women each year in the United States alone might be spared the side effects of this drug or similar ones without significantly raising the risk their cancer will return. That would be roughly half of all breast cancer patients who get chemo now.
In the study, Taxol did the most good for women who had overactive HER-2 genes — the target of the newer breast cancer drug Herceptin. These women were about 40 percent less likely to have a recurrence if they received Taxol.
Conversely, Taxol did not significantly help women whose tumors were HER-2 negative and were being helped to grow by estrogen. This is the most common form of the disease.
The differences were revealed by a new analysis of a study done in the 1990s, using modern genetic tools that were not available at that time.
"The days of 'one size fits all' therapy for patients with breast cancer are coming to an end," Dr. Anne Moore of Weill Cornell Medical College wrote in an editorial accompanying the study in today's New England Journal of Medicine. "Oncologists have a responsibility to their patients to be aware of this report."
The original study involved more than 3,000 women whose cancer had spread to nearby lymph nodes but not widely throughout the body. This is the situation of about one-fourth of the 175,000 women diagnosed with breast cancer in the U.S. each year.
Researchers tested adding paclitaxel, sold as Taxol by New York-based Bristol-Myers Squibb Co. and now also in generic form. They gave it after surgery to remove the cancer and treatment with the chemo drugs Adriamycin and Cytoxan.
Taxol improved survival and became a new standard of care. But the drug frequently causes neurological side effects including numbness and tingling in the hands and feet. In the original study, 18 percent of women had this problem months and even years after taking Taxol.
The study was paid for by grants from the federal government and a breast cancer foundation.
To read the complete Associated Press report on the study, visit: http://ap.google.com/article/ALeqM5gnqBJfw6XlNjK4sBpZTAP8PBIJ0QD8S6K0HG0
October is National Breast Cancer Awareness Month. Bay State Parent magazine produced Think Pink: A Guide Devoted to Breast Cancer Awareness in the October issue. To read the article in the guide visit:http://baystateparent.com/
Bay State Parent magazine is also a sponsor of the American Cancer Society's 15th Annual Making Strides Against Breast Cancer Walk THIS Sunday, Oct 14. For more information, visit http://main.acsevents.org/site/TR?JServSessionIdr005=wunev07mg2.app26b&pg=entry&fr_id=3496&JServSessionIdr005=wunev07mg2.app26b